share_log

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38

Canaccord Genuity 维持对Corcept Therapeutics的买入,将目标股价提高至38美元
Benzinga ·  2023/12/13 11:48

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $37 to $38.

Canaccord Genuity分析师爱德华·纳什维持Corcept Therapeutics(纳斯达克股票代码:CORT)的买入,并将目标股价从37美元上调至38美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发